Another explanation for the benefit in cardiomyocytes is that empagliflozin could reduce Ca2+/calmodulin-dependent kinase II (CaMKII) activity in both HF murine and human ventricular cardiomyocytes to improve contractility, since increased CaMKII levels are considered as hallmarks of HF (12). Here, CAMK2G is linked to hydrops fetalis.